SCM
ASND icon

Superstring Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Superstring Capital Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,754
Closed -$1.93M – 41
2024
Q1 		$1.93M Buy
+12,754
New +$1.82M 1.27% 23

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Superstring Capital Management's ASND Position: Q2 2024 in Review

Superstring Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2024, closing a stake of 12,754 shares — an estimated $1.93M sold.

Superstring Capital Management first reported a position in ASND in Q1 2024 and held it in 1 quarter. The position peaked at $1.93M in Q1 2024. 203 funds tracked by Wall St. Rank hold ASND as of Q2 2024.

  • Superstring Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2024 after selling out during the quarter.
  • Superstring Capital Management sold 12,754 Ascendis Pharma A/S shares in Q2 2024, an estimated $1.93M.
  • Superstring Capital Management first reported a position in Ascendis Pharma A/S in Q1 2024 and held it in 1 quarter.
  • Superstring Capital Management's Ascendis Pharma A/S position peaked at $1.93M in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2024.

Based on Superstring Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.